Safety and Immunogenicity of Recombinant Herpes Zoster Vaccine (CHO Cells) in Healthy Subjects Aged 18 Years and Above
Safety and Immunogenicity of Recombinant Herpes Zoster Vaccine (CHO Cells) in Healthy Subjects Aged 18 Years and Above
Active, not recruiting · NCT05636436 · Registry updated 2024-11-20Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Safety and Immunogenicity of Recombinant Herpes Zoster Vaccine (CHO Cells) in Healthy Subjects Aged 18 Years and Above | DNA Virus Infections, Herpesviridae infectious disease, Infections, Varicella Zoster Virus Infection, herpes zoster, viral infectious disease | Active, not recruiting | Phase 1 | 2024-11-20 | NCT05636436 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Henan Center for Disease Control and Prevention | 7 |
| MAXVAX Biotechnology Limited Liability Company | 10 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Yanjin District Center for Disease Control and Prevention | Xinxiang | China | 1 |